Skip to main content
. 2023 Aug 1;12(17):18405–18417. doi: 10.1002/cam4.6386

FIGURE 3.

FIGURE 3

Significant pathways associated with current regular‐dose aspirin use in the 1–2 years prior to ovarian cancer diagnosis compared with never regular‐dose aspirin use in type II ovarian tumor tissue in Nurses' Health Study (NHS), Nurses' Health Study II (NHSII), and New England Case–Control Study (NECC) (false discovery rate (FDR) <0.01). Pathways associated with current regular‐dose aspirin use are presented in the order of statistical significance and FDR plotted on the x‐axis. Upregulated pathways are denoted by red bubbles, and downregulated pathways are denoted by blue bubbles.